THC Therapeutics Acquisition of SugarTop Buddery has been confirmed in an all-share transaction valued at approximately $3 million, entirely settled through newly issued Series D Preferred stock. This strategic acquisition further strengthens THC Therapeutics, Inc. (OTC: THCT) as it builds a bi-coastal, vertically integrated cannabis platform in the United States.
This latest acquisition follows THCT’s purchase of The Headquarters Group in June 2025 and signals the company’s commitment to acquiring well-established, culturally significant cannabis operators. By incorporating SugarTop Buddery into its portfolio, THC Therapeutics enhances its operational footprint in Oregon, a market known for both its potential and its operational challenges.
SugarTop Buddery Joins THC Therapeutics Acquisition Portfolio
Founded in 2015, SugarTop Buddery has emerged as a community-focused, female-founded cannabis brand with deep roots in the Pacific Northwest. Despite revenue contraction from a peak of $4.3 million in 2022 to $2.1 million in 2024, SugarTop Buddery remains renowned for its innovative music collaborations, retro-inspired branding, and commitment to craft cultivation.
The THC Therapeutics Acquisition of SugarTop Buddery includes the parent company STHoldings Group LLC, which owns STB Enterprises LLC (operations), STIP (intellectual property), and STH Enterprises LLC (hemp-focused subsidiary). This structure provides THCT with valuable assets and intellectual property to drive growth and market penetration.
Female Leadership and Cultural Authenticity Add Brand Value
Anna Kaplan, CEO and co-founder of SugarTop Buddery, brings a decade of leadership within Oregon’s competitive cannabis industry. She commented that the deal ensures the brand’s longevity and broader reach, stating that joining THC Therapeutics offers the infrastructure and investment required for national expansion.
Scott Cox, CEO of THC Therapeutics, highlighted that SugarTop Buddery’s legacy aligns perfectly with THCT’s roll-up strategy. He emphasised that the brand’s authenticity, loyal customer base, and experienced leadership team strengthen the company’s ability to compete in a fragmented market.
Strategic Fit for Bi-Coastal, Vertically Integrated Operations
The THC Therapeutics Acquisition of SugarTop Buddery complements THCT’s existing operations and supports its ambition to create a robust, bi-coastal cannabis platform. By targeting established brands with proven operational resilience and cultural significance, THCT aims to deliver long-term shareholder value while honouring the spirit of the communities it serves.
As part of its broader growth plan, THC Therapeutics will continue to identify operators that share its commitment to integrity, sustainability, and authentic brand storytelling. The acquisition preserves cash reserves through an all-share transaction structure but does result in shareholder dilution via new Series D Preferred stock issuance.
Despite Oregon’s competitive market dynamics, the addition of SugarTop Buddery’s pre-roll leadership, contract manufacturing capabilities, and strong brand recognition positions THC Therapeutics to scale efficiently and profitably.
